Moberg Pharma AB
πΈπͺSweden
- Country
- πΈπͺSweden
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.mobergderma.se
Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design
Phase 1
Completed
- Conditions
- Erythema
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 45
- Registration Number
- NCT06369675
- Locations
- πΊπΈ
TKL Research, Inc, Fair Lawn, New Jersey, United States
Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design
Phase 1
Completed
- Conditions
- Erythema
- Interventions
- Drug: MOB015BDrug: MOB015B vehicleDrug: Negative irritant solution of 0.9% saline
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 250
- Registration Number
- NCT06369727
- Locations
- πΊπΈ
TKL Research, Inc, Fair Lawn, New Jersey, United States
A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
Phase 3
Active, not recruiting
- Conditions
- Onychomycosis
- Interventions
- Drug: MOB015BDrug: Vehicle (Placebo Comparator)
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 350
- Registration Number
- NCT05279846
- Locations
- π¨π¦
Toronto Research Centre, Toronto, Ontario, Canada
πΊπΈIMA Clinical Research, Monroe, Louisiana, United States
πΊπΈWeill Cornell Medicine Dermatology, New York, New York, United States
A Study of the Systemic Absorption of MOB015B
Phase 1
Completed
- Conditions
- Onychomycosis
- Interventions
- Drug: MOB015B
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 20
- Registration Number
- NCT03244280
- Locations
- πΊπΈ
Dermatology clinic, Austin, Texas, United States
Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
Phase 3
Completed
- Conditions
- Distal Subungual Onychomycosis
- Interventions
- Drug: MOB015B
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 452
- Registration Number
- NCT02866032
A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
Phase 3
Completed
- Conditions
- Distal Subungual Onychomycosis
- Interventions
- Drug: MOB015BDrug: MOB015B Vehicle
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 365
- Registration Number
- NCT02859519
An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
Phase 2
Completed
- Conditions
- Distal Subungual Onychomycosis
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Moberg Pharma AB
- Registration Number
- NCT01814020
- Locations
- πΈπͺ
Hudkliniken Sahlgrenska Universitetssjukhuset, Gothenburg, Sweden
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
Phase 2
Completed
- Conditions
- Actinic Keratosis
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Moberg Pharma AB
- Registration Number
- NCT01611480
- Locations
- π©πͺ
5 Locations, Germany, Germany
A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- Moberg Pharma AB
- Registration Number
- NCT01567683
- Locations
- π©πͺ
Proinnovera GmbH Phase I Unit, Munster, Germany
Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 250
- Registration Number
- NCT01246518
- Locations
- πΈπͺ
15 Locations, Sweden, Sweden
Β© Copyright 2025. All Rights Reserved by MedPath